A glucagon‐like peptide‐1 (<scp>GLP</scp>‐1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

Thondam, S. K.; Cuthbertson, Daniel J.; Aditya, B. S.; MacFarlane, I. A.; Wilding, John; Daousi, Christina

doi:10.1111/j.1365-2265.2012.04368.x

Cited by 24 publications

(21 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that a GLP-1 analogue, exenatide, is effective in increasing satiety as well as improving diabetes in patients with Prader-Willi syndrome (15,16). Very recently, a woman with a hypothalamic tumor treated with radiotherapy who developed hypothalamic obesity and diabetes was successfully treated with exenatide, as indicated by a decrease in both body weight and HbA1c as well as an improvement in her abnormal eating behaviors (17). Similarly, GLP-1 analogues have been successfully used to treat several patients with obesity and diabetes associated with hypothalamic tumors (18).…”

Section: Discussionmentioning

confidence: 99%

Liraglutide as a Potentially Useful Agent for Regulating Appetite in Diabetic Patients with Hypothalamic Hyperphagia and Obesity

et al. 2014

View full text Add to dashboard Cite

Hypothalamic hyperphagia and obesity are characterized by a lack of satiety and an abnormally high appetite that is difficult to control. We herein report the cases of two patients with hypothalamic hyperphagia and obesity with MRI-detectable hypothalamic lesions. These patients suffered from diabetes mellitus associated with an abnormal eating behavior and weight gain. Liraglutide was successfully used to treat their diabetes mellitus and suppress their abnormal appetites. Glucagon-like peptide-1 analogues, including liraglutide, are promising treatment options in patients with hypothalamic hyperphagia and obesity, as these agents enhance the hypothalamic input of the satiety signal, which is lacking in such patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Liraglutide as a Potentially Useful Agent for Regulating Appetite in Diabetic Patients with Hypothalamic Hyperphagia and Obesity

et al. 2014

View full text Add to dashboard Cite

show abstract

“…An open-label and a double-blind, placebocontrolled trial with the somatostatin agonist octreotide in children with HO has demonstrated weight loss and weight stabilisation along with reductions in insulin levels (21,22). There is limited evidence for the use of sibutramine (23,24), dextroamphetamine (25,26), metformin (27), GLP-1 receptor agonists (28), supraphysiological doses of T 3 (29) and melatonin (30) as treatments in HO in both children and adults. No studies of orlistat in the HO population exist; however, its use has been mentioned in only a few case reports.…”

Section: Discussionmentioning

confidence: 99%

“…age at last clinic assessment was 44G16.5 years. There was a highly significant increase in median BMI, from 28 ) at the last followup (P!0.0001), a median of 9 years after diagnosis of their tumour. Weight gain was fastest within the first year after diagnosis of their tumour, with an increase in mean BMI to 30.4 kg/m 2 (P!0.0001); the rate of weight gain subsequently declined but did not plateau.…”

Section: Longitudinal Changes In Weight and Bmimentioning

confidence: 96%

Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic

Steele

Cuthbertson

MacFarlane

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Obesity is highly prevalent among adults with acquired, structural hypothalamic damage. We aimed to determine hormonal and neuroanatomical variables associated with weight gain and obesity in patients following hypothalamic damage and to evaluate the impact of early instigation of weight loss measures to prevent or limit the severity of obesity in these patients. Design: Retrospective study of 110 adults with hypothalamic tumours attending a specialist neuroendocrine clinic. BMI was calculated at diagnosis and at last follow-up clinic visit. Endocrine data, procedures, treatments and weight loss measures were recorded and all available brain imaging reviewed. Results: At last follow-up, 82.7% of patients were overweight or heavier (BMIR25 kg/m 2 ), 57.2% were obese (BMIR30 kg/m 2 ) and 14.5% were morbidly obese (BMIR40 kg/m 2 ). Multivariate analysis revealed that use of desmopressin (odds ratio (OR)Z3.5; PZ0.026), GH (ORZ2.7; PZ0.031) and thyroxine (ORZ3.0; PZ0.03) was associated with development of new or worsened obesity. Neuroimaging features were not associated with weight gain. Despite proactive treatments offered in clinic in recent years (counselling, dietetic and physical activity advice, and anti-obesity medications), patients have continued to gain weight. Conclusions: Despite increased awareness, hypothalamic obesity is difficult to prevent and to treat. Improved understanding of the underlying pathophysiologies and multicentre collaboration to examine efficacy of novel obesity interventions are warranted.

show abstract

“…Zoicas et al showed that patients with HO who were treated with either liraglutide (n = 1) or exenatide (n = 8) lost 13 kg of body weight on average, and the weight loss was maintained over 6 to 44 months . In other case reports of the efficacy of GLP‐1 receptor agonists in HO, substantial and sustained weight loss was also observed in patients . These overall results suggest that GLP‐1 receptor agonists may enhance the hypothalamic input of the satiety signal and thus appears to be an important therapeutic option in patients with HO and obesity.…”

Section: Resultsmentioning

confidence: 97%

Current and emerging therapies for managing hyperphagia and obesity in Prader‐Willi syndrome: A narrative review

et al. 2019

View full text Add to dashboard Cite

Summary In early childhood, individuals with Prader‐Willi syndrome (PWS) experience excess weight gain and severe hyperphagia with food compulsivity, which often leads to early onset morbid obesity. Effective treatments for appetite suppression and weight control are currently unavailable for PWS. Our aim to further understand the pathogenesis of PWS led us to carry out a comprehensive search of the current and emerging therapies for managing hyperphagia and extreme weight gain in PWS. A literature search was performed using PubMed and the following keywords: “PWS” AND “therapy” OR “[drug name]”; reference lists, pharmaceutical websites, and the ClinicalTrials.gov registry were also reviewed. Articles presenting data from current standard treatments in PWS and also clinical trials of pharmacological agents in the pipeline were selected. Current standard treatments include dietary restriction/modifications, exercise, and growth hormone replacement, which appear to have limited efficacy for appetite and weight control in patients with PWS. The long‐term safety and effectiveness of bariatric surgery in PWS remains unknown. However, many promising pharmacotherapies are in development and, if approved, will bring much needed choices into the PWS pharmacological armamentarium. With the progress that is currently being made in our understanding of PWS, an effective treatment may not be far off.

show abstract

A glucagon‐like peptide‐1 (GLP‐1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

Cited by 24 publications

References 12 publications

Liraglutide as a Potentially Useful Agent for Regulating Appetite in Diabetic Patients with Hypothalamic Hyperphagia and Obesity

Liraglutide as a Potentially Useful Agent for Regulating Appetite in Diabetic Patients with Hypothalamic Hyperphagia and Obesity

Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic

Current and emerging therapies for managing hyperphagia and obesity in Prader‐Willi syndrome: A narrative review

Contact Info

Product

Resources

About